Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine

Journal of Clinical Oncology

Volumn 28, Issue 30, 2010, Pages 4554-4561

  Perotti, Antonella ^a   Locatelli, Alberta ^a   Sessa, Cristiana ^a   Hess, Dagmar ^a   Viganò, Lucia ^a   Capri, Giuseppe ^a   Maur, Michela ^a   Cerny, Thomas ^a   Cresta, Sara ^a   Rojo, Federico ^a   Albanell, Joan ^a   Marsoni, Silvia ^a   Corradino, Irene ^a   Berk, Lori ^a   Rivera, Victor M ^a   Haluska, Frank ^a   Gianni, Luca ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; FLUOROURACIL; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; RIDAFOROLIMUS; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; EIF4EBP1 PROTEIN, HUMAN; PHOSPHOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TYMP PROTEIN, HUMAN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; DERMATITIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIUM CELL; ERYTHEMA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN METABOLISM; PUNCH BIOPSY; RASH; SIGNAL TRANSDUCTION; SKIN CULTURE; SKIN FISSURE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; BIOPSY; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; EUROPE; GRANULATION TISSUE; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; MULTICENTER STUDY; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; SKIN; TREATMENT OUTCOME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; FLUOROURACIL; GRANULATION TISSUE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKOCYTES, MONONUCLEAR; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; SIROLIMUS; SKIN; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 78049513393     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.5867     Document Type: Article

References (40)

1. Adjei AA, Hidalgo M: Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol 23:5386-5403, 2005 (Pubitemid 46206992)
2. Bjornsti MA, Houghton PJ: The TOR pathway: A target for cancer therapy. Nat Rev Cancer 4:335-348, 2004
3. Rathmell WK, Wright TM, Rini BI: Molecularly targeted therapy in renal cell carcinoma. Expert Rev Anticancer Ther 5:1031-1040, 2005 (Pubitemid 43033793)
4. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721-732, 2003
5. Janus A, Robak T, Smolewski P: The mammalian target of the rapamycin (mTOR) kinase pathway: Its role in tumourigenesis and targeted antitumor therapy. Cell Mol Biol Lett 10:479-498, 2005 (Pubitemid 41564520)
6. Fasolo A, Sessa C: mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs 17:1717-1734, 2008
7. Kwitkowski VE, Prowell TM, Ibrahim A, et al: FDA approval summary: Temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 15:428-435, 2010
8. Yuan R, Kay A, Berg WJ, et al: Targeting tumorigenesis: Development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2:45, 2009
9. Clackson T, Metcalf CA, Rivera VM, et al: Broad antitumor activity of ap23573, an mTOR inhibitor in clinical development. Proc Am Soc Clin Oncol 22:220, 2003 (abstr 882).
10. Mita MM, Mita AC, Chu QS, et al: Phase I trial of the novel mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 26:361-367, 2008 (Pubitemid 351171685)
11. Hartford CM, Desai AA, Janisch L, et al: A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res 15:1428-1434, 2009
12. Yatscoff R, LeGatt D, Keenan R, et al: Blood distribution of rapamycin. Transplantation 56:1202-1206,1993 (Pubitemid 23348701)
13. Rizzieri DA, Feldman E, Dipersio JF, et al: A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 14:2756-2762, 2008
14. Matsuzaki T, Yashiro M, Kaizaki R, et al: Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci 100:2402-2410, 2009
15. Rivera VM, Tang H, Metcalf CA III, et al: Anti-proliferative activity of the mTOR inhibitor AP23573 in combination with cytotoxic and targeted agents. Proc Amer Assoc Cancer Res 45:89, 2004 (abstr 3887)
16. Walko CM, Lindley C: Capecitabine: A review. Clin Ther 27:23-44, 2005 (Pubitemid 40347299)
17. Brown NS, Bicknell R: Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem J 334:1-8, 1998 (Pubitemid 28420963)
18. Moghaddam A, Zhang HT, Fan TP, et al: Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci U S A 92:998-1002, 1995
19. Miyadera K, Sumizawa T, Haraguchi M, et al: Role of thymidine phosphorylase activity in the angiogenic effect of platelet-derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res 55:1687-1690, 1995
20. Haraguchi M, Miyadera K, Uemura K, et al: Angiogenic activity of enzymes. Nature 368:198, 1994
21. Sawada N, Ishikawa T, Fukase Y, et al: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4:1013-1019,1998 (Pubitemid 28183404)
22. Seeliger H, Guba M, Koehl GE, et al: Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin Cancer Res 10:1843-1852, 2004
23. Punt CJ, Boni J, Bruntsch U, et al: Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluoruracil and leucovorin in patients with advanced solid tumors. Ann Oncol 14:931-937, 2003 (Pubitemid 36827210)
24. Heggie GD, Sommadossi JP, Cross DS, et al: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203-2206, 1987 (Pubitemid 17074634)
25. Swain SM, Lippman ME, Egan EF, et al: Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7:890-899, 1989 (Pubitemid 19172462)
26. Peters GJ, van Triest B, Backus HH, et al: Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. Eur J Cancer 36:916-924, 2000 (Pubitemid 30214143)
27. Welsh SJ, Titley J, Brunton L, et al: Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues. Clin Cancer Res 6:2538-2546, 2000 (Pubitemid 30399226)
28. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, June 10, 2003 update. Bethesda, MD, National Cancer Institute, National Institutes of Health, 2003
29. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
30. Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM): Guidance for Industry: Bioanalytical Method Validation. May 2001. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf
31. Zufía L, Aldaz A, Giráldez J: Simple determination of capecitabine and its metabolites by liquid chromatography with ultraviolet detection in a single injection. J Chromatogr B Analyt Technol Biomed Life Sci 809:51-58, 2004
32. Gibaldi M, Perrier D: Pharmacokinetics. New York, NY, Marcel Dekker, 1982
33. Déporte-Féty R, Picot M, Amiand M, et al: High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: Application to measurement of dihydropyrimidine dehydrogenase activity. J Chromatogr B Biomed Sci Appl 762:203-209, 2001 (Pubitemid 32913429)
34. Evrard A, Cuq P, Ciccolini J, et al: Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Br J Cancer 80:1726-1733, 1999 (Pubitemid 29389624)
35. Tabernero J, Rojo F, Calvo E, et al: Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26:1603-1610, 2008
36. Veldman PH, Reynen HM, Arntz IE, et al: Signs and symptoms of reflex sympathetic dystrophy: Prospective study of 829 patients. Lancet 342:1012-1016, 1993 (Pubitemid 23314802)
37. Fujioka S, Yoshida K, Yanagisawa S, et al: Angiogenesis in pancreatic carcinoma: Thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival. Cancer 92:1788-1797, 2001 (Pubitemid 32952497)
38. Chen LC, Hsueh C, Tsang NM, et al: Heterogeneous ribonucleoprotein k and thymidine phosphorylase are independent prognostic and therapeutic markers for nasopharyngeal carcinoma. Clin Cancer Res 14:3807-3813, 2008
39. Soong R, Shah N, Salto-Tellez M, et al: Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol 19:915-919, 2008 (Pubitemid 351627307)
40. Seck K, Riemer S, Kates R, et al: Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res 11:5886-5892, 2005 (Pubitemid 41170317)